Literature DB >> 16397267

Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.

Annette I Garbe1, Benjamin Vermeer, Jaba Gamrekelashvili, Reinhard von Wasielewski, Florian R Greten, Astrid M Westendorf, Jan Buer, Roland M Schmid, Michael P Manns, Firouzeh Korangy, Tim F Greten.   

Abstract

Treatment options for pancreatic cancer are limited and often ineffective. Immunotherapeutic approaches are one possible option that needs to be evaluated in appropriate animal models. The aim of the present study was to analyze tumor-specific immune responses in a mouse model of pancreatic cancer, which mimics the human disease closely. C57BL/6 EL-TGF-alpha x Trp53-/- mice, which develop spontaneous ductal pancreatic carcinoma, were generated. EL-TGF-alpha x Trp53-/- mice developed spontaneous pancreatic tumors with pathomorphologic features close to the human disease. Tumor-specific CD8+ T-cell responses and IgG responses were analyzed in EL-TGF-alpha x Trp53-/- mice during tumor development and compared with mice with s.c. growing pancreatic tumors. In contrast to spontaneous pancreatic tumors, cell lines generated from these tumors were rejected after s.c. injection into wild-type mice but not in nude or RAG knockout mice. Direct comparison of spontaneous and s.c. injected tumors revealed an impaired infiltration of CD8+ T cells in spontaneous pancreatic tumors, which was also evident after adoptive transfer of tumor-specific T cells. Intratumoral cytokine secretion of tumor necrosis factor-alpha, IFN-gamma, IL-6, and MCP-1 was lower in spontaneous tumors as well as the number of adoptively transferred tumor-specific T cells. Our data provide clear evidence for tumor-specific immune responses in a genetic mouse model for pancreatic carcinoma. Comparative analysis of s.c. injected tumors and spontaneous tumors showed significant differences in tumor-specific immune responses, which will help in improving current immune-based cancer therapies against adenocarcinoma of the pancreas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397267     DOI: 10.1158/0008-5472.CAN-05-2383

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Authors:  William W Tseng; Daniel Winer; Justin A Kenkel; Okmi Choi; Alan H Shain; Jonathan R Pollack; Randy French; Andrew M Lowy; Edgar G Engleman
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

Review 2.  Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 3.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

Review 4.  Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer.

Authors:  J D Liao; N V Adsay; F Khannani; D Grignon; A Thakur; F H Sarkar
Journal:  Histol Histopathol       Date:  2007-06       Impact factor: 2.303

5.  Orthotopic inflammation-related pancreatic carcinogenesis in a wild-type mouse induced by combined application of caerulein and dimethylbenzanthracene.

Authors:  Chen Liang; Zhen Wang; Li Wu; Chen Wang; Bao-Hua Yu; Xiu-Zhong Yao; Xiao-Lin Wang; Ying-Yi Li
Journal:  Tumour Biol       Date:  2015-04-29

Review 6.  Inflammatory networks and immune surveillance of pancreatic carcinoma.

Authors:  Robert H Vonderheide; Lauren J Bayne
Journal:  Curr Opin Immunol       Date:  2013-02-17       Impact factor: 7.486

7.  Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma.

Authors:  Fei Zhao; Sonja Obermann; Reinhard von Wasielewski; Lydia Haile; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

8.  Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma.

Authors:  Fei Zhao; Benjamin Vermeer; Ulrich Lehmann; Hans Kreipe; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

Review 9.  Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.

Authors:  Georg Feldmann; Anirban Maitra
Journal:  J Mol Diagn       Date:  2008-02-07       Impact factor: 5.568

Review 10.  Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.

Authors:  Michel DuPage; Tyler Jacks
Journal:  Curr Opin Immunol       Date:  2013-03-04       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.